ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Lupin Ltd.

Company Background

Lupin is a major generic drugmaker that conducts business in more than 100 countries. Among India's five biggest pharmaceuticals, it has about 10 production bases in India and exports generic drugs to other countries.

It was founded in 1968 by Desh Bandhu Gupta, a researcher at a science university. Since the early 2000s, it has been actively buying companies in South Africa, Mexico, even Japan.

It got a head start on its Indian competitors by building a supply network in Japan. It did so in 2007 by acquiring Kyowa Pharmaceutical Industry, an Osaka-based medium-size generic drugmaker. In 2014, it set up a venture with Yoshindo, a generic drug company based in Japan's Toyama Prefecture, to jointly develop generic biomedicines.

Zyma Laboratories, an affiliate company run by Desh Bandhu Gupta and other executives, is Lupin's top shareholder; the founding family still owns some shares in Lupin.

Business Summary

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. It offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2021 INRUSD
Revenue150,249.50M2,023.97M
Gross Profit45,055.70M606.93M
Operating income17,142.80M230.92M
Income before tax16,751.20M225.65M
Net income12,165.30M163.87M
EBITDA25,677M345.88M
Diluted EPS26.720.36
Dividends Per Share6.500.08
Total Assets236,104.40M3,229.27M
Total liabilities97,523.30M1,333.85M
Total equity138,022.20M1,887.77M
Operating cash flow17,296.30M232.99M
Currency in INRCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 170,090.50M 155,509.10M 144,095.60M 151,619.10M 150,249.50M
Gross Profit 83,802.20M 60,769.20M 41,652.90M 41,517.40M 45,055.70M
Operating income 33,543.30M 18,628.40M 15,088.80M 12,171.10M 17,142.80M
Income before tax 35,348.90M 5,432.90M 14,052.10M 7,532.90M 16,751.20M
Net income 25,574.60M 2,512.60M 5,120.90M -3,994.90M 12,165.30M
EBITDA 42,665.60M 30,899.40M 23,549.30M 21,873.30M 25,677M
Diluted EPS 56.46 5.54 13.35 -5.95 26.72
Dividends Per Share 7.50 5 5 6 6.50
Total Assets 266,072.80M 263,053.80M 279,493.70M 249,838.50M 236,104.40M
Total liabilities 130,751.90M 126,882.40M 141,602.80M 123,953.10M 97,523.30M
Total equity 134,966.50M 135,761.40M 137,413.10M 125,357.80M 138,022.20M
Operating cash flow 40,092.80M 15,901M 14,897.10M 12,562.80M 17,296.30M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 2,536.50M 2,412.26M 2,060.19M 2,138.31M 2,023.97M
Gross Profit 1,249.71M 942.65M 595.52M 585.52M 606.93M
Operating income 500.22M 288.96M 215.73M 171.65M 230.92M
Income before tax 527.14M 84.27M 200.90M 106.23M 225.65M
Net income 381.38M 38.97M 73.21M -56.34M 163.87M
EBITDA 636.25M 479.31M 336.69M 308.48M 345.88M
Diluted EPS 0.84 0.08 0.19 -0.08 0.36
Dividends Per Share 0.11 0.07 0.07 0.08 0.08
Total Assets 4,097.52M 4,033.22M 4,034.55M 3,302.50M 3,229.27M
Total liabilities 2,013.58M 1,945.40M 2,044.06M 1,638.48M 1,333.85M
Total equity 2,078.48M 2,081.53M 1,983.58M 1,657.04M 1,887.77M
Operating cash flow 597.89M 246.65M 212.99M 177.17M 232.99M

Valuation Measures

Mar 2021
PER38.04
ROA5.00%
ROE9.23%
Operating margin11.40%
Profit margin8.09%

Key executives

  • Chief Executive Officer & Executive Director: Vinita D. Gupta
  • Global CFO & Executive Director: Ramesh Swaminathan
  • CEO-US Generics, Head-Biosimilars, Global R&D: Alok Sonig
  • President-Global Quality & Compliance: Johnny Mikell
  • Managing Director & Executive Director: Nilesh Deshbandhu Gupta

Shareholders

  • Lupin Investments Pvt Ltd. (45.2%)
  • Life Insurance Corp of India (7.8%)
  • HDFC Asset Management Co. Ltd. (Invt Mgmt) (4.0%)
  • ICICI Prudential Asset Management Co. Ltd. (2.5%)
  • The Vanguard Group, Inc. (1.6%)
  • National Pension System Trust (1.4%)
  • Norges Bank Investment Management (1.3%)
  • BlackRock Fund Advisors (1.2%)
  • Comgest SA (1.1%)
  • Franklin Templeton Asset Management (India) Pvt Ltd. (1.1%)

Contact Details

  • Website:http://www.lupin.com
  • Address: Kalpataru Inspire, Off Western Expressway Highway, Mumbai, 400055, India
  • Phone: +91.22.66402323

Related Companies

  • Lupin Europe GmbH LLC
  • Lupin Japan & Asia Pacific KK
  • Lupin Latam, Inc.
  • Lupin Pharma LLC
  • Medquimica Industria Farmaceutica
  • Lupin Middle East FZ LLC
  • Generic Health Sdn. Bhd.
  • Lupin Philippines, Inc
  • Bellwether Pharma Pty Ltd.
  • Lupin Mexico SA de CV
  • Lupin Pharma Canada Ltd.
  • Lupin Holdings BV
  • Lupin Management, Inc.
  • Lupin Research, Inc.
  • Lupin, Inc.
  • VeeGo Pharma LLC
  • Lupin Atlantis Holdings SA
  • Lupin Farmaceutica Do Brasil Ltda.
  • Lupin Pharmaceuticals Ltd/Brazil/
  • Lupin Employees Benefit Trust
  • Nanomi BV
  • Lupin Healthcare Ltd.
  • Gavis Pharmaceuticals LLC
  • Lupin Chemical (Thailand) Ltd.
  • Lupin Australia Pty Ltd.
  • Lupin Holdings B.V., Netherlands
  • Polynova Industries Ltd.
  • Lupin Laboratories Ltd.
  • Laboratorios Grin SA de CV
  • Lupin Pharmaceuticals, Inc.

Competitors

  • Amneal Pharmaceuticals, Inc. Class A
  • Teva Pharmaceutical Industries Limited
  • Aurobindo Pharma Ltd
  • Cadila Healthcare Limited
  • Dr. Reddy's Laboratories Ltd.
  • Amneal Pharmaceuticals, Inc. Class A
  • Midatech Pharma Plc
  • Dare Bioscience, Inc.
  • Agile Therapeutics, Inc.
  • Bora Pharmaceuticals Co Ltd
  • TherapeuticsMD, Inc.
Last Updated on 27 Oct, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more